Moreover, the expression of proBDNF on ASCs has a significant clinical correlation with the auto-antibody level and disease activity of patients with SLE, indicating that ASCs+ proBDNF+ cells can be used as a clinical marker of SLE. This evidence concerns the gene BDNF and systemic lupus erythematosus.